Q8T.F OrbusNeich Medical Group Holdings Limited
- Market cap
- EUR 298M
- P/E
- 7.2x
- P/B
- 0.80x
- ROE
- 10.1%
- Dividend yield
- 4.99%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is Q8T.F undervalued?
Graham numberQ8T.F trades 49.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OrbusNeich Medical Group Holdings Limited fundamental analysis
No fundamental analysis for OrbusNeich Medical Group Holdings Limited yet.
OrbusNeich Medical Group Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited, an investment holding company, engages in the manufacture, trading, sale, and marketing of medical devices/instruments for the treatment of coronary and peripheral vascular diseases. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, drug-coated balloons and stents for lesion therapy, non-compliant balloons for post-dilatation, and specialty catheters, as well as microcatheters…
Full company profileOrbusNeich Medical Group Holdings Limited financial statements
OrbusNeich Medical Group Holdings Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 116M | 137M | 154M | 164M | 180M |
| Gross Profit | 81.2M | 92.5M | 106M | 114M | 122M |
| Operating Income | 20.4M | 24.1M | 39.4M | 35.2M | 40.0M |
| EBITDA | - | 27.1M | 54.0M | 47.9M | 53.5M |
| Net Income | -4.44M | 18.5M | 45.1M | 39.7M | 41.9M |
| EPS | -0.01 | 0.02 | 0.05 | 0.05 | 0.05 |
| Balance Sheet | |||||
| Total Assets | 269M | 351M | 410M | 431M | 453M |
| Total Liabilities | 85.4M | 28.5M | 40.7M | 36.6M | 38.7M |
| Shareholders' Equity | 183M | 323M | 368M | 393M | 413M |
| Cash & Short-term Investments | 176M | 229M | 256M | 249M | 219M |
| Cash Flow | |||||
| Operating Cash Flow | 20.5M | 23.4M | 23.0M | 13.1M | 19.5M |
| Capital Expenditure | 2.14M | 3.34M | 7.48M | 11.3M | 18.4M |
| Free Cash Flow | 18.4M | 20.1M | 15.6M | 1.84M | 1.15M |
| Ratios | |||||
| ROE | -2.4% | 5.7% | 12.2% | 10.1% | 10.1% |
| ROA | -1.7% | 5.3% | 11.0% | 9.2% | 9.3% |
| Net Profit Margin | -3.8% | 13.5% | 29.3% | 24.2% | 23.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OrbusNeich Medical Group Holdings Limited dividends
- Dividend yield
- 4.99%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 63.4%
- Ex-dividend date
- Sep 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 26.5M | 0.03 | 63.4% |
| 2024 | USD 10.6M | 0.01 | 26.7% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns OrbusNeich Medical Group Holdings Limited
- Insiders 63.73%
- Institutions 11.68%
- Public & others 24.59%
- Shares outstanding 823M
- Free float 225M
OrbusNeich Medical Group Holdings Limited company profile
- Company name
- OrbusNeich Medical Group Holdings Limited
- Ticker
- Q8T.F
- ISIN
- KYG6773B1005
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 1,528
- Fiscal year end
- December
- Address
- Building 20E, Sha Tin, Hong Kong
- Phone
- 852 2802 2288
- Website
- orbusneich.com
About OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited, an investment holding company, engages in the manufacture, trading, sale, and marketing of medical devices/instruments for the treatment of coronary and peripheral vascular diseases. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, drug-coated balloons and stents for lesion therapy, non-compliant balloons for post-dilatation, and specialty catheters, as well as microcatheters, guide catheter extension, dual therapy, and drug eluting stents. Its product portfolio covers various treatment processes in percutaneous coronary intervention and percutaneous transluminal angioplasty procedures. It operates in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, the United States, and internationally. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.
OrbusNeich Medical Group Holdings Limited management
5- Mr. David ChienChairman of the Board & Co-CEO · born 1965
- Ms. Kwai Ching LauCo-CEO & Executive Director · born 1975
- Mr. Wing Shing ChenCOO & Executive Director · born 1982
- Ms. Man Ying ChanCFO & Company Secretary · born 1975
- Mr. Alain Djamel KhairChief Commercial Officer · born 1970